Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Rabies vaccine (Vero cell) is an inactivated viral vaccine being developed by AIM Vaccine Co. for the prevention of rabies. Produced using the Vero cell line—a continuous lineage of African green monkey kidney epithelial cells—the vaccine contains inactivated rabies virus that serves to stimulate the host's immune system to produce neutralizing antibodies. AIM Vaccine Co., a prominent Chinese vaccine manufacturer and the world's second-largest supplier of human rabies vaccines, is advancing this candidate as part of its extensive rabies portfolio. While the company already markets a freeze-dried Vero cell rabies vaccine, this specific candidate is currently in the research and preclinical development phase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rabies vaccine (Vero cell).